US 12,077,510 B2
Carboxylic acid compounds
Seiji Hori, Osaka (JP); Futoshi Hasegawa, Osaka (JP); Daisuke Urabe, Osaka (JP); and Hirotaka Kurebayashi, Osaka (JP)
Assigned to Sumitomo Pharma Co., Ltd., Osaka (JP)
Filed by Sumitomo Pharma Co., Ltd., Osaka (JP)
Filed on Mar. 2, 2022, as Appl. No. 17/653,256.
Application 17/653,256 is a division of application No. 16/736,660, filed on Jan. 7, 2020, granted, now 11,299,465.
Application 16/736,660 is a continuation of application No. 16/167,974, filed on Oct. 23, 2018, granted, now 10,562,861.
Application 16/167,974 is a continuation of application No. 15/152,497, filed on May 11, 2016, granted, now 10,150,743, issued on Dec. 11, 2018.
Application 15/152,497 is a continuation of application No. 14/401,366, granted, now 9,376,398, issued on Jun. 28, 2016, previously published as PCT/JP2013/064420, filed on May 17, 2013.
Claims priority of provisional application 61/806,158, filed on Mar. 28, 2013.
Claims priority of provisional application 61/648,816, filed on May 18, 2012.
Prior Publication US 2022/0267282 A1, Aug. 25, 2022
Int. Cl. C07D 239/48 (2006.01); C07D 239/47 (2006.01); C07D 239/49 (2006.01); C07D 403/10 (2006.01); C07D 403/12 (2006.01); A61K 31/505 (2006.01); A61K 31/506 (2006.01)
CPC C07D 239/48 (2013.01) [C07D 239/47 (2013.01); C07D 239/49 (2013.01); C07D 403/10 (2013.01); C07D 403/12 (2013.01); A61K 31/505 (2013.01); A61K 31/506 (2013.01); Y02P 20/55 (2015.11)] 4 Claims
 
1. A pharmaceutical composition comprising:
at least one compound selected from the group consisting of:
2-((4-((2-amino-4-(1-hydroxyhexan-3-ylamino)-6-methylpyrimidin-5-yl)methyl)-3-methoxybenzyl)(2,2-difluoroethyl)amino)acetic acid,
2-((4-((2-amino-4-(1-hydroxyhexan-3-ylamino)-6-methylpyrimidin-5-yl)methyl)-3-methoxybenzyl)(2,2,2-trifluoroethyl)amino)acetic acid,
(S)-2-((4-((2-amino-4-(1-hydroxyhexan-3-ylamino)-6-methylpyrimidin-5-yl)methyl)-3-methoxybenzyl)(2,2-difluoroethyl)amino)acetic acid,
(S)-2-((4-((2-amino-4-(1-hydroxyhexan-3-ylamino)-6-methylpyrimidin-5-yl)methyl)-3-methoxybenzyl)(2,2,2-trifluoroethyl)amino)acetic acid, and
pharmaceutically acceptable salts of any of the foregoing, and at least one pharmaceutically acceptable diluent or carrier.